Dysifragilone A inhibits LPS‑induced RAW264.7 macrophage activation by blocking the p38 MAPK signaling pathway

  • Authors:
    • Huixiang Li
    • Qian Zhang
    • Xin Jin
    • Xiaowen Zou
    • Yuexuan Wang
    • Dexiang Hao
    • Fenghua Fu
    • Weihua Jiao
    • Cuixia Zhang
    • Houwen Lin
    • Keiichi Matsuzaki
    • Feng Zhao
  • View Affiliations

  • Published online on: October 26, 2017     https://doi.org/10.3892/mmr.2017.7884
  • Pages: 674-682
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dysifragilone A, a sesquiterpene aminoquinone based on a rearranged avarone skeleton, has been previously isolated and identified from the South China Sea sponge Dysidea fragilis. In the present study, anti‑inflammatory activity and the underlying molecular mechanism of dysifragilone A were studied using the classical inflammation model of lipopolysaccharide (LPS)‑activated RAW264.7 macrophage cells and an MTT assay, Griess method, ELISA and western blotting were used. The results revealed that dysifragilone A significantly reduced the release of inflammatory mediators and inflammatory cytokines in activated RAW264.7 cells, including nitric oxide (NO), prostaglandin E2,(PGE2) and interleukin‑6 (IL‑6). The protein expression levels of inducible nitric oxide synthase (iNOS), cyclooxygenase‑2 (COX‑2), and the enzymatic activity of iNOS and COX‑2 were also inhibited by dysifragilone A in a dose dependent manner. Further mechanistic investigations suggested that the anti‑inflammatory activity of dysifragilone A results from the suppression of p38 mitogen‑activated protein kinase (MAPK) activation in LPS‑activated macrophages; however, this was not associated with inhibition of the extracellular signal‑regulated kinase (ERK) or c‑Jun N‑terminal kinase (JNK) signaling pathways. Therefore, dysifragilone A and similar compounds may be anti‑inflammatories that have potential to be used in the clinic.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 17 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Li H, Zhang Q, Jin X, Zou X, Wang Y, Hao D, Fu F, Jiao W, Zhang C, Lin H, Lin H, et al: Dysifragilone A inhibits LPS‑induced RAW264.7 macrophage activation by blocking the p38 MAPK signaling pathway. Mol Med Rep 17: 674-682, 2018
APA
Li, H., Zhang, Q., Jin, X., Zou, X., Wang, Y., Hao, D. ... Zhao, F. (2018). Dysifragilone A inhibits LPS‑induced RAW264.7 macrophage activation by blocking the p38 MAPK signaling pathway. Molecular Medicine Reports, 17, 674-682. https://doi.org/10.3892/mmr.2017.7884
MLA
Li, H., Zhang, Q., Jin, X., Zou, X., Wang, Y., Hao, D., Fu, F., Jiao, W., Zhang, C., Lin, H., Matsuzaki, K., Zhao, F."Dysifragilone A inhibits LPS‑induced RAW264.7 macrophage activation by blocking the p38 MAPK signaling pathway". Molecular Medicine Reports 17.1 (2018): 674-682.
Chicago
Li, H., Zhang, Q., Jin, X., Zou, X., Wang, Y., Hao, D., Fu, F., Jiao, W., Zhang, C., Lin, H., Matsuzaki, K., Zhao, F."Dysifragilone A inhibits LPS‑induced RAW264.7 macrophage activation by blocking the p38 MAPK signaling pathway". Molecular Medicine Reports 17, no. 1 (2018): 674-682. https://doi.org/10.3892/mmr.2017.7884